Kenvue Inc.

Hello and welcome to Kenview second quarter, 2025 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakers remarks, there will be a question and answer session. Who would like to ask a question during this time simply press star 1 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host Sophia to send us head of investor relations for can view.

Good morning everyone and welcome to can be second quarter, 2025 earnings conference call. I'd like to extend a special welcome to Kirk Perry interim chief executive officer and I'm at the Nadi chief financial officer as they participate in their first earnings call with us today. Before we get started. I'd like to remind you that today's call includes forward looking statements regarding among other things are operating and financial performance market opportunities and growth. These statements represent our current beliefs expectations or assumptions about future events and are subject to various risks uncertainties and changes that are difficult to predict and could cause our actual results to differ materially For information regarding these risks and uncertainties, please refer to our earnings materials related to this call posted on our website and our filings of the SEC During this call, we will reference certain non gap financial information. The presentation of this non gap financial information is not intended to be considered an isolation or the substitute for financial information presented in accordance with the US gap. These non gap financial measures should be viewed in conjunction with the most directly comparable US gap financial measures and are not presented a substitute for or superior to those most directly comparable US gap financial measures. Those most directly comparable US gap financial measures and a reconciliation of our non gap items to their respective nearest US gap measures. Can be found in this morning's earnings press release and our presentation available in our IR page of Kenviews website .kenview.com with that I'll turn it over to Kirk.

Thank you, Sophia and good morning everyone. We appreciate you joining us today. I'm honored to be speaking with you for the first time as interim CEO. I've had the pleasure of serving on the Kenview board since late last year. It is a privilege to take on this new role. It's such an important time for the company. Our full board is acting with urgency, making changes in leadership, working to Kenview on an accelerated growth trajectory and progressing our comprehensive review of strategic alternatives. I clearly see the opportunity where I can step in and make a difference right away, drawing on my past experiences. If more than 30 years in the global CPG technology and data and analytics industries, I am committed to leveraging my knowledge and expertise to make an impact quickly enabling Kenview to deliver on its tremendous potential. During my 23 years at Procter & Gamble, I competed against many of Kenview's iconic brands and I bring deep consumer, customer and operational experience in our categories. During this time, I spent six years working abroad in South Korea and Japan, gaining important insights into what it takes to win across diverse and dynamic markets outside the US. I was also responsible for running P&G's US operations group, overseeing all the North American marketing and US operations teams, deeply integrating into our customer teams to grow and win with our largest retail partners. I bring a tech-first understanding of the global consumer marketplace from my time at Serkana and Google. As CEO of Serkana, the global tech, data and analytics provider for the consumer retail and media sectors, I led the team that helped global clients successfully navigate the data and AI revolution. At Google, I was president of Global Client Agency Solutions, where we helped the world's largest advertisers and agencies win in the digital first world. My time at these companies shaped how I see the modern playbook for consumer brands, something that has transformed dramatically and rapidly in a data-driven, digitally enabled world and something that CPG companies need to embrace to win with consumers and customers. To win, we need to adopt not only the right tools, but the right mindset across everything we do. The reason I'm so confident in Kenview turnaround is that I've been part of many over the course of my career. Probably the single biggest and most dramatic was turning around the baby care business at P&G during the time I was there, where I had the opportunity to lead the Northeast Asia and then the North America businesses. Over a two-year period, we strengthened the performance of a big business that had been losing share for years by focusing on the fundamentals we executed with excellence and turned it around. There has been important progress made in the business since Kenview was established as a standalone company, with Kenviewers working to transition processes and systems and separate from J&J to create a stronger, tailored business foundation and beginning to achieve efficiencies and cost savings along the way. Of course, with the separation now behind us, we have to find ways to work smarter and be more agile by simplifying work streams and streamlining decision making. The focus is on improving our execution and financial performance in order to deliver reliable and consistent results. I am a firm believer that promises made need to be promises kept. To that end, I'll now turn to some of the key points we want to leave you with today. The Kenview board has taken a set of decisive actions to enable the company to unlock shareholder value and reach its full potential. The board asked me to step into the CEO role on an interim basis following the earlier CFO transition with Amit Banati joining the company. Amit is here with us on his first earnings call today and is now three months into his role. Speaking for the board and the company, we are very pleased to have someone with Amit skills and relevant experiences in this critical role. In addition to these leadership changes, the board has previously initiated a comprehensive review of strategic alternatives and we now have a strategic review committee in place, which I'm a member of, to oversee this ongoing process. We are considering a broad range of potential alternatives, including optimizing the company's brand portfolio. Amit and I are working closely with other members of the board on this process. We're moving with rigor and urgency to deliver the best outcome for our shareholders and we'll update everyone as the review progresses. I also want to be clear that while the board's work proceeds, we are not standing still and we are actively and acutely focused on improving our operational and financial performance. Pennview has an iconic brand portfolio with so much potential. Potential without performance doesn't matter. We need to enable these brands to live up to their full potential faster in a sustainable manner. We will be moving at warp speed to get the business moving in the right direction. In the three weeks since I've been in the interim CEO role, I've been diligently digging into the business to identify what we're doing well and what we need to change to win with consumers and customers and operate with greater impact and agility. While I'm still in my early days and going through deep dives across the entire organization, I wanted to share some initial observations which have informed our immediate priorities. There is a significant amount of complexity across the organization. Whether it comes to SKUs, brands or even countries, we can't be everything to everyone and we need to be more choiceful on where to play and how to win. Even when it comes to innovation, by focusing on fewer, bigger and better ideas, we can execute better and more efficiently. But that said, I do want to acknowledge that in the back half of the year, we have the most robust pipeline of innovation we've had in years. Second, we should be winning share with our brands, period. To make this a reality, we need to transition to a consumer centric mindset. The consumer should always be at the center of everything we do. When you do this well, it shows up everywhere. From iconic brand marketing campaigns to breakthrough innovation that drives category growth to organizing everything you do on systems, processes and structure to delight our boss, the consumer. As an organization, we need to refocus on household penetration, which is key to driving market share. Deep consumer understanding creates incredible consumer insights that deliver points of difference we can leverage to drive big ideas and needle moving innovation. We simply haven't done this well enough. When you deeply understand the consumer, you build insights that are the foundation of everything you do. It leads to brand building that resonates and allows your brand to move from consumers liking it to needing it. Then you build innovation from the insights that delight and reinforce it through marketing. And last but certainly not least, flawless go to market execution is absolutely critical to our success. Whether it comes to category management, revenue growth management, perfect store or how we show up online, in particular with e-commerce. Executing with excellence is mandatory, not optional. It is something we have not done, but absolutely need to do well everywhere. Importantly, none of these are insurmountable challenges. Members of our leadership team and I have already run this playbook before and I'm confident we can do it again. The good news is that over the past few weeks, I've also seen an organization that wants to win. They want us to refocus on fundamentals and make bold choices. By focusing on the following four immediate priorities, I believe we can reach our goals faster. Our first priority is to strengthen leadership and capabilities. We are pleased that Andy Dasgupta, a nearly 30 year global consumer products industry veteran, assumed leadership of our Asia Pacific region in July. With extensive leadership experience in health, nutrition and food and beverage sectors, Andy has held senior level regional and global roles across Europe, the US and Asia Pacific. And today we announced that Mike Wondrash will serve as our new Chief Technology and Data Officer, effective August 25th, bringing nearly 30 years of experience at the intersection of technology, digital and data for global Fortune 100 companies. These appointments complement the many new talents and capabilities we have brought in across the organization to accelerate our marketing, sales, digital and AI capabilities across our markets. Ensuring that we have the right leadership and capabilities in place to improve performance is a critical focus area for me. With these moves, we've appointed four new leaders to Kenview's leadership team over the past three months, which is one third of the team. Second, we'll also take a fresh look at our operating strategy. As I mentioned earlier, our focus will be on making the right choices on where to play and how to win. Unfortunately, what has inhibited our ability to do this well to date is that we have created self induced complexity that we need to fix. A few examples. While we have 115 brands in the company, 41 play a role across one or more regions and account for over three fourths of our sales. We have a long tail of SKUs that make up a significant portion of total SKUs, yet account for approximately 1% of our sales. Finally, we have a robust pipeline of innovation, but far too many initiatives that can be executed efficiently and effectively. We can and we will do better here. Third, improving execution will be the core of everything. My mentor once told me the only strategy our consumers and customers ever see is our execution. And I obsess over three critical moments of truth and execution. It's when consumers hit the zero moment of truth, which is where they become aware of our brands. The first moment of truth is when consumers find us on the shelves or online. And the second moment of truth is when consumers use our product and decide to repurchase it or not. Simply put, we need to win with our biggest brands and our biggest customers in our biggest markets. Because we win here, we win. Our 10 biggest brands in each region account for more than two thirds of our sales and our 10 biggest markets account for more than three quarters of our sales. Lastly, we'll review ways to optimize our structure and operating model. The limits test here is simple. Does the model we have enable us to make decisions as fast as possible and win with consumers and customers? If not, how do we adjust course to be a simpler, more agile, higher impact organization? I'm the big believer that lots of different operating models can work if you are laser focused on enabling the right decisions at the right level with speed and precision. All of these priorities need to work in harmony for us to grow our market share and win in market. So while it's not a complicated formula, we're determined to get it right and energized by the opportunities we have ahead. I'll now turn to an overview of top line results for Q2 before Amit does a deeper dive on the financials. We faced a tough quarter and our top line results were well below expectations. While organic sales declined 4.2%, global consumption grew year over year and outpaced organic sales across each segment. Results in self care were disproportionately impacted by unfavorable seasonal and customer inventory dynamics, which masked strong market share performance for the business. For example, in the US, 83% of our business held or gained share and analogy, despite the soft season, Zyrtec didn't just strengthen its leadership position, but also grew household penetration across both adult and children franchises. In skin health and beauty, while we still have work to do to get back to market share gains and consistent top line growth, we are encouraged by the sequential improvement in consumption in the US. Neutrogena Face, a key platform for the brand, returned to year over year consumption growth in the US during the quarter, with market share trends also improving sequentially. Globally, consumption of our skin health and beauty brands stabilized for the first time in more than a year, fueled by growth in EMEA, Latin America, and Asia Pacific. In essential health, we perform well in Latin America, but face declines in other regions against a strong year ago quarter. We have stepped up our efforts to increase household penetration for Listerine and in Q2 launched our global Wash Your Mouth campaign in the US, which has since been activated across other major markets such as Canada, UK, Germany, and China. From a regional perspective, we are pleased with our performance in EMEA and Latin America. Although Q2 results were impacted by external dynamics, ultimately, we did not execute at the level we should have. In light of Q2 results and current expectations through the end of the year, we have revised guidance for 2025. Now I'll turn it over to Amit for more on our financial results and outlook.

Thank you Kirk and good morning everyone. I'm pleased to be here for my first earnings call with Kenview. While our iconic brands and geographic footprint initially attracted me to the company, ultimately I joined because I saw and continue to be excited about the significant opportunity for value creation as we unlock the full potential of our brands. Similarly to Kirk, I have extensive experience in global consumer packaged goods companies, having spent more than 30 years working in different countries across the globe, both in finance and operational leadership roles. Equally important and relevant to us today is my strong background in leading businesses through transformation and strategy evolution. Over the past three months, I have immersed myself in the business by conducting deep dives with our teams, meeting with both Kenviewers and external stakeholders to understand our strengths and opportunities and working closely with our board to advance our ongoing strategic review. Although it's still early days, I would like to share a few initial observations and the financial priorities that I'll be focusing on, which are closely aligned with what Kirk has just discussed. Clearly, we are not delivering on our growth potential and our results have not been consistent or reliable. Enhancing operating rigor and discipline will be a key priority for me. We have a significant opportunity to improve our overall integrated business planning process with a particular focus on consumption driven demand forecasting. Addressing this will be critical to driving consistency and reliability in our results. Another priority will be driving efficiencies and getting to appropriate peer benchmark levels across the P&L. This will provide fuel for our growth, while also enabling us to expand margins over time. While our gross margins are at healthy levels and the company has made good progress over the past years, we can realize further improvements over time by continuing to drive strong productivity across our supply chain through further procurement, network optimization, planning and digitization initiatives. Strengthening our revenue growth management capability with an immediate focus on our top markets and driving margin enhancing innovation. On SG&A, recognizing the sizable lift of separation and the fact that Kenview recently became a standalone company, our costs are above comparable benchmarks. This represents an opportunity going forward and work is underway to identify additional sources of cost savings as we look to get to levels commensurate with the potential of our brands within the categories and regions in which we operate. While we have increased our investments behind our brands closer to peers, we have opportunities to optimize our spend and drive higher ROI on our brand investments. Work on this is underway as we speak. On cash flow, we have opportunities in working capital. As we continue to transform the supply chain, we expect to see benefits across inventory and payables and improve cash flow conversion. A key enabler will be modernizing and optimizing our systems, processes and technologies. Through the separation and TSA exits, the company cloned legacy infrastructure that we are modernizing as we look to drive our digital and data strategies and realize productivity and efficiency opportunities. During my short tenure, it is clear to me that while we have significant strengths, there is also substantial work to do both in support of the review of strategic alternatives and to drive operational improvements that will accelerate profitable and sustainable growth while providing consistency and reliability for investors. Now I will provide additional color on our second quarter results as well as the revised outlook for the year. As we shared several weeks ago in quarter two, organic sales declined 4.2%, which was below our expectations and I'll discuss the drivers shortly. On margins, SG&A savings helped offset the impact of softer gross margins so that adjusted operating margin contracted 10 basis points versus last year to .7% with adjusted diluted EPS coming in at 29 cents versus 32 cents in the year ago period. Let's dive deeper into our top line performance in the quarter. Organic sales in quarter two declined 4.2%. While global consumption was positive and significantly outpaced organic sales performance across each segment, this was a disappointing result in what remains a dynamic macro backdrop. In addition to execution being below expectations, there were four other major drivers of our sales performance in the quarter. First, our categories decelerated sequentially versus quarter one and year over year and our share performance is not where it needs to be. Second, soft allergy and sun care seasons in our largest markets weighed on replenishment orders during the quarter. Third, there was a negative impact on top line from both trade inventory fluctuations at certain customers in the US across all segments and changes in shipment timing versus last year in China. And lastly, strategic investments in price in the US weighed on value realization. As a result of these factors, both value realization and volumes were unfavorable in quarter two, contracting .9% and .3% respectively. Looking at the segments, our self care business was most significantly impacted by the inventory and seasonal dynamics across North America and Asia Pacific regions. Self care is where we saw the largest gap between consumption, which grew year over year and organic sales, which contracted .9% largely due to lower volumes. From a category perspective, while we continue to drive strong momentum on our smoking cessation business as we built on the rollout of NICOR-8 lozenges across global markets, organic sales declined year over year across the allergy as well as cuff cold and flu and pain care franchises. These businesses were not only impacted by a decline in seasonal incidences in quarter two of this year, but also lapped against an inventory build in China for the 24th season, which, as you may recall, ended up being very weak. In allergy, a reduction in incidence hindered category performance across our two key markets, US and China. In the US, allergy incidences in quarter two were the second lowest on record, with adults and children's incidences declining .7% and .9% respectively. Despite these category headwinds, which also weighed on replenishment orders, Zyrtec continued to strengthen its leadership position, gaining both share and household penetration behind excellent execution of a packaging refresh and strong promotional and media support. In China, while the allergy category was also weak, Rhinocote gained share. Despite top-flying softness, self-care remains a bright spot when it comes to the strength of our brands and the underlying health of the business. In the US, 83% of our business held or gained share. Our largest brand in self-care, Tylenol, continued to gain share, as this was the 12th consecutive quarter of share improvement in the US for adult Tylenol. Importantly, Tylenol also continues to be at the forefront of innovation as we leverage and extend this excellent brand equity into adjacent categories. For example, we are adding Tylenol Precise Nighttime to the Precise lineup. Furthermore, we are also meeting evolving consumer needs as we recently launched the new Children's Tylenol Natural Apple flavor, which provides a new dye-free formula that does not have artificial flavoring. Turning to skin health and beauty, where organic sales decreased .7% versus last year, as value realization and volume declined 2.3 and 1.4%, respectively. Solid organic sales growth across EMEA and Latin America regions was offset by declines in North America and Asia Pacific. Encouragingly, global consumption stabilized for the first time since the third quarter of 2023, with similar drivers behind the sizable gap relative to organic sales as I just laid out for self-care. In our largest market, the US, despite weak sun care category performance during the quarter, overall consumption trends continue to improve sequentially, benefiting from the strategic price investments the team implemented starting in quarter four of last year across some of our brands. At the same time, the team's brand building efforts behind Neutrogena Face and OGX are resonating with consumers as consumption for these two platforms inflected back into positive territory during the quarter. In fact, the OGX Bond Protein Repair launch has been the number one performing innovation from Kenview year to date and has helped secure additional distribution for the brand. While we are encouraged by these improvements, we also recognize there is considerable work to do to get back on a sustainable growth and share gain trajectory for the US business. As we continue to focus on turning around this important business and bring new product innovation to the market this fall, we will be agile and disciplined with our investments to ensure they drive strong returns. Organic sales for essential health decreased .4% as volume and value realization contracted 1.8 and .6% respectively. In addition to cycling against the strongest comparison of 2024 as essential health registered .6% organic sales growth in the year ago period. Similarly to the other segments, there was a disconnect between consumption and top line performance. This was most pronounced in wound care, which fundamentally is on a good footing as Band-Aid brand adhesive bandages grew share with strong performance from the new product lineup such as Band-Aid waterproof and tie-dye. We're making progress addressing competitive pressures in women's health in Asia Pacific and are encouraged by the consumption of our baby care brands. However, we're not satisfied with the performance of our mouthwash business in the US where despite gaining share online, we're losing share across the total universe. Even as the brand continues to deliver strong growth on the premium line. The teams are urgently working through plans to arrest the share decline, which we have slowed relative to last year through actions we have taken to be more competitive on our base business. The key challenge our teams are addressing is on our portfolio mix where we are not playing strongly enough in the fastest growing mild alcohol free segment. Our first step is our recently launched wash your mouth campaign, which is showing positive early reads. There are strong marketing and customer activation plans in place to support the campaign and this shift. The new campaign will be coupled with new product launches as a second step. But we do expect that it will take some time to get back to share gains. Moving down the P&L, adjusted gross margin contracted 70 basis points versus last year to 60.9%. Our supply chain team continued to drive strong productivity, which was more than offset by the headwinds from input cost inflation, unfavorable mix, currency and strategic price investments. Relative to last year, adjusted operating income declined .5% with adjusted operating margin contracting 10 basis points to 22.7%. We lapped against a significant step up in brand support in the year ago period and adjusted our crews for incentive compensation, which contributed to the SG&A leverage in the quarter. Gross savings from our view forward also continue to track to expectations and contributed to the year over year reduction in SG&A costs. Adjusted net income in quarter two came in at $560 million with adjusted diluted EPS at 29 cents, including about a penny headwind from foreign exchange. Below the line items were unfavorable year over year and contributed to the .3% decline in adjusted net income. Net interest expense went up about $2 million to $94 million and the adjusted effective tax rate increased to .9% from .7% as we lapped a discrete tax benefit in the year ago period. We are revising our outlook for 2025 to reflect the year to date results as well as our current expectations for the second half, considering the dynamic external environment and underlying business fundamentals. For 2025, we currently expect organic sales to be down low single digits with about neutral impact from currency. While we continue to plan for greater contribution from innovations in the back half of the year, we believe a more muted outlook is warranted on the base business, given year to date performance, fluctuation in retailer order patterns and the sequential slowdown in our categories in quarter two. We are assuming adjusted operating margin will contract versus last year, largely as a result of strategic price investments, fixed cost, deleverage and inflationary pressures, which we do not expect to be fully offset with productivity initiatives. The tariff backdrop remains very fluid, but based on what is currently in effect, we expect gross annualized impact to be around $150 million and below that in 2025, given the timing of tariffs. Given the top line shortfall, we are taking urgent actions to curtail our discretionary spend and accelerate productivity measures. Within this outlook, we plan to continue supporting our brands at a higher level than last year, although you should fully expect us to be much more choiceful in our investments as we are laser focused on redirecting spending towards higher ROI ideas. Taking these factors into account and maintaining the same below the line assumptions gets us to a full year adjusted diluted EPS in the range of $1 to $1.05, including a low single digit drag from currency. We are not satisfied with our performance in the second quarter and the results we currently expect for the full year. We are committed to moving with speed to improve our operating performance and financial results and are making the necessary interventions to strengthen the business. And now I'll turn it back over to Kirk for closing remarks.

Thanks, Amit, for walking through that detail. Our results are not where we want them to be and we're going to focus on our four operating priorities to drive and improve performance. As we move forward, I am focusing the team on where we are doing well, what I'll call glimpses of greatness, so that we can search and reapply proven business building use cases. Let me share a few examples. We are leveraging our investments with healthcare professionals through increased and integrated sales forces, stronger sampling and more competitive claims to drive share gains. Tylenol, which is the number one healthcare professional recommended brand, continues to expand our pain leadership position through impactful brand campaigns and communications, increased total distribution points and strong innovation. Another example is our ability to scale successes across geographies through our international Nicorette franchise, which is driving top line growth for the brand. We continued our streak of seven consecutive quarters of share gains by increasing distribution for lozage and gum and broader brand activations in top EMEA markets and globally. Lastly, but certainly not least, we know how to turn businesses around in high growth competitive markets. Our team in Brazil has done exactly that with Johnson's Baby, the world's number one baby care brand that elevates precious moments of bonding by launching consumer centric innovation. Leveraging revenue growth management to improve competitiveness, strengthening ROI and enhanced communications, we just realized our second quarter of year over year share growth and re-clicking the number one prescribed brand through strong healthcare professional engagement and increased total distribution points. I want to wrap up with a few important points. The company's recent performance is below what we believe we can achieve and the board is committed to taking decisive actions to unlock shareholder value. We're taking a fresh look at the business and providing an updated guidance range today that we are confident in. We've also outlined our immediate operating priorities to get us there. We're focused on having the right leadership. We're focused on flawless execution and faster decision making to enable and advance the right operating strategy. Our goal of accelerating profitable growth is not changing. We're just revisiting how we can deliver it. At the same time, our review of strategic alternatives is underway and the board is considering a broad range of potential alternatives. I want to close by saying a huge and heartfelt thank you to our more than 20,000 Ken viewers for the warm welcome in my first few weeks and in its first three months. Change is not easy, but I love the passion and desire to win that I sense from this organization. I see it, hear it, and feel it. It's an honor to step into this role at this important time. I look forward to keeping you updated and progress

in the months ahead. With that, we'll open up the call to questions.

Thank you. At this time, we'll be conducting a question and answer session. In the interest of time, we ask that you please limit yourself to one question to allow us for as many questions as possible. If you have a question, please press star one on your telephone keypad. To withdraw your question, simply press star two. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star key. One moment, please, for your first question. Our first question comes from the line of Lauren Lieberman with Barclays. Please proceed with your question.

Great. Thanks so much. So, that was a lot of great color. And I just wanted to talk maybe a little bit about timeframe, around the idea of we're identifying key operating goals and things we can do up front, relative to the evaluation that's going on in the what to do sort of next in the background. And is it fair to think about that because the complexity piece is a big one when I think about sort of the challenges for the enterprise as a whole. So, is it reasonable to think about the biggest brands, the biggest countries, the biggest innovations, focus the dollars there now, do that immediately and up the game. And it's really about evaluating how do we deal with the complexity, the tail brands, the tail countries, the smaller businesses. And that's the big, I guess, the biggest element of the strategic review work. Thanks.

Thank you, Lauren. It's good to hear from you again.

So, at a high level, what you said is absolutely true. We need to focus, and as I mentioned, in terms of the number of brands, as an example, the Contributory, three-quarters, three-quarters of our sales, the long tail of SKUs that make up less than 1% of our sales, great innovation pipeline, but just too many initiatives. So, I was thinking about this last night. You know, when I was in high school, our wrestling coach made us wrestle someone two weight classes up to prepare for the season. It was always easier in the match because you were wrestling someone that's much heavier. And I feel like in a lot of ways, we're wrestling someone many weight classes above our weight because we built in this complexity. And so, being focused and executing flawlessly on these core things, the biggest brands, the biggest countries, the biggest initiatives to help us grow more quickly is definitely it. You know, I'll give you three examples where I think, you know, in terms of executional excellence, we can fine tune these things quickly to be able to see a difference. One example is we need to be where the consumers are. And if you look at what our business split is between brick and mortar and e-comm, we're significantly overdeveloped in brick and mortar, but we're significantly underdeveloped in e-comm. We need to win in e-comm. It's growing faster. If we just grow with the category in e-comm, we're going to pick up significantly in our businesses because they are growing there. So we can make that pivot, make that shift, do that much better and hold ourselves accountable for that. On our initiatives, one example is our Listerine Total Care recent initiative. It's growing significantly faster in the category. We have user generated content up 245%. Share of voice is the highest in the category. Denison Hygenist ratings number one. Yet we're not growing fast enough. We're sequentially improving, but we're not growing positively from a share standpoint. The problem there is a leaky bucket, right? The core has to be strong. So while we're launching and supporting initiatives, we need to make sure our core is strong. So we're going to go through and review and make sure every one of our core brand is supporting our core as well as our innovation to make sure that we grow. And then the last example I'll give you an Executional Excellence so we can get our hands around quickly is in media or ROI, we are improving. But that's broken down into a couple components. One is our efficiency from a CPM standpoint. And the second is our effectiveness. What we're seeing is our efficiency is way better because we're investing in CTMs that allow us to get a scale benefit. They're less expensive. But our effectiveness in total is not as strong as it can be. So the net of that is positive. But if we had our efficiency up and our effectiveness up across our top brands in our top countries on our top initiatives, we would be accelerating growth. So those are just a few examples where our execution can be improved and we will work on that. And the other thing, Lauren, I just I would be remiss to say is you mentioned this strategic alternatives review, the board and our leadership team have been hand in hand on this. And you know, I call this the power of and we are going through this strategic alternatives review and making sure that we look at every potential possibility. In addition to operating the company better. It's not an or it's an and. So we need to do both these things well as Amit said in his comments that I mentioned. We need to make sure we're predictable, reliable and consistent.

Thank you. Our next question comes from the line of Peter Graham with UBS. Please proceed with your question.

Thanks, Operator. And good morning, everyone. So Kirk, maybe following up on that, you touched on your experience and how that frames your view on kind of the modern CPG playbook. Your commentary on initial observations and priorities were helpful both in the prepared remarks as well as your response to Lauren, but maybe taking a step back. I'd be curious when you when you stepped into the role. What were kind of some of the biggest surprises from your standpoint. And then as we think about the top line turnaround, I, you know, As you look at the brands or categories or regions, I'd be curious, where are you most excited about the past forward and maybe conversely, where do you

think improvement may be more challenging. Thanks. Thank you, Peter, for that question.

So what was I most surprised about when I came in, I would tell you that and I mentioned this when I when I had my prepared remarks, I was surprised by what I would call the self induced complexity that we have created. You know, it's just, it's just an inhibitor to be able to move faster to be agile and to be able to drive the results we need to drive on the businesses. But, you know, I've seen this before. I've experienced this before. And our ability to move quickly to enable the reduction of that complexity is going to be absolutely crucial because we have incredible brands. That was one of the reasons I initially joined the board. And I am even more encouraged by seeing them live and up close. And Amit mentioned that, you know, Tylenol has had 12 consecutive quarters of growth. You know, Avino Baby has had nine consecutive quarters growth. We have pockets where we're doing exceptionally well. So where I'm excited is where we're able to focus. We are able to see results. And I think, you know, we've seen sequential improvement in Neutrogena face as an example, because we've been exceptionally focused there. So it's a proof point that we can win there. You know, we've got, you know, one of the challenges we have in skin health and beauty is we have a long tail. And so that long tail makes it challenging when you're focused on a few core elements to get the whole piece moving in tandem together up into the right. But as we get in, as we make our assessments and, you know, make choices, as I talk about the where to play and how to win, you know, we'll get that right. You know, one of the one of the great things I've seen so far, where am I excited, is what we've been able to do in EMEA and LATAM has been, you know, a encouragement because you see where we've been focused, where we have been more focused on the execution elements and getting the details right. We've been able to win with consumers. We've been able to win with customers and go up and to the right. I think our challenges, as you've heard from our results, you know, from a regional standpoint, we're most challenging APAC and in North America, where we will continue to be focused. And as I talked about those execution elements, continue to focus on them and get those pieces right. But I also believe that, like I said, even in the APAC and North America regions, we have those pockets where we're winning. We just have to operate this model at scale. Take those learnings and get them across the majority of the business as quickly as we possibly can to get those proof points that allow us to get that flywheel

moving that we need to get moving.

Thank you. Our next question comes from the line of Javier Escalante with Evercore ISI. Please proceed with your question.

Good morning, Kirk, Ahmed, Sofia. Thank you for the question. I want to go back to the theme of complexity. Kirk, you were at P&G where the turnaround and the reduction of complexity involved actually business divestitures and in attractive categories, product or divested, pet care, preferences. And the concept there was that because of retail and competitive dynamics were structurally challenged. So if you could discuss kind of like your views of the framework, the board is going to be looking into how to unlock value when you look at, say, skin health, where you have the lowest profitability of the portfolio. And at the same time, you have very tough competitive dynamics that intersect bigger players, shifting retail. So if you can give us, I understand the notion of simplifying smaller things. That is obvious. But I think that at P&G, there were other elements, not just cooling, SKU, proliferation. Thank you.

Yeah, thank you for that question, Javier. And

I

think

the way we have talked about this and we will continue to be focused is our strategic alternatives and our operational excellence work are an and. We're in lockstep with the board on that. And we're going to continue to look at every single value creator that we can. And so that is going to happen. We're not going to obviously come in and any individual business segment, individual business or segment while we do that. But I also know and believe that execution has played a big role in our performance today or under performance and getting that right with strong capabilities is going to go a long way. And you're right in pointing out that there are different elements of the P&G turnaround. And I think what's very similar is our iconic and resilient brands. And we have incredible growth potential in that portfolio. We've got to get our consumer understanding right. That's going to create these product and marketing insights. They're going to deliver points of difference. We've got to translate that into brand building excellence, which is big ideas, content and media excellence, digital ecom. We've got to innovate with fewer, bigger and better. We need to scale those things across our brands and platforms and regions and then go to market excellence, which is category management. Revenue growth management. Perfect store. Those are things that we can control. And I think the important thing too is we've been talking to the team and really been focused on what it is that we can control. What we can control is demand creation. That's our job. It's figuring out how to generate those ideas, which resonate with consumers that are going to grow our businesses. What we can't control is the macro environment or what's happening because of that in individual categories or a retail partner's decision on working capital management and what levels of inventory they carry. We can obviously influence those things, but what we can control is generating demand. And that's we're going to be singularly focused

on and making sure that we do that well.

Thank you. Our next question comes from the line of Andrea Tashara with JP Morgan. Please proceed with your question.

Thank you all and Kirk. I mean, I appreciate all and you, Amit, as well, how you are shaping this restructuring. But as we think about timing, and I know you can't, we can talk about timing at this point, but thinking about how to measure success in this endeavor. Like you did comment on the success of the Brazilian turnaround and some of the pockets that you pointed out in even in skin health and beauty and in baby. But just to think how you're going to be putting your team accountable for in terms of like how the skin health and beauty obviously was the one that that was pointed out as a low hanging fruit. But it seems like you've been able to turn around some of the pockets there with Neutrogena face. How we should be thinking as we progress and you have a CMO who is also looking at improving on that area. How are you going to measure that and how can shareholders and investors look at, you know, either be it numerator or Nielsen, how we could be seeing like that success or even Amazon the data for for beauty, how we should be monitoring that that progress.

Yeah, thank you, Andrea for the for the question. And I think,

you

know, in

terms of measuring success, I mean, the ultimate success is going to be determined by consumers voting for us every day at the shelf. And so we need to be holding ourselves accountable for seeing sequential improvement in that vote. And so, like I just mentioned, you know, we can't necessarily control what's happening in a macro environment, but we do have to be able to do that. And so what we can't control is consumers voting for our brands online at shelf and coming back and buying them again. And so we are expecting, you know, as we fine tune our model. You know, I mentioned earlier, you know what those things are and focus areas for me and what it's going to take to improve. I think it's making sure we have the right leaders in the right chairs and build the right capabilities. You know, we've appointed new leaders on our on 40 leaders in the last three months in our business, about a third of our team. We're building capabilities and you know what I call the modern modern CPG world in the marketing, sales, digital and AI spaces. We're going to be much more choiceful on where to win and how to win, where to play. We're going to improve our execution. I gave several examples today where we're going to dig in as a leadership team and make sure we are monitoring. Every one of these pieces be very, very focused on getting it right quickly. And then making sure we have the right operating structure and model so that we give the organization the opportunity to win. But at the end of the day, it is very simple. Are we sequentially improving with consumers voting for us

relative to seeing improvement in our share?

Thank you. Our next question comes from the line of Steve powers with Deutsche Bank. Please proceed with your question.

Great. Thank you. Good morning. Kirk. Good morning. Good morning. So,

as you as you run this strategy, prioritize focus and simplicity and reducing complexity, I guess two questions are hanging in my mind. If you were to do that organically. Question number one is, how big a headwind to organic growth would that be as you reduce the complexity and kind of cut the tail on complexity? Is it just that kind of lowest and observed percentages of excess skews you need to carve out or is there kind of a bigger piece, a bigger headwind to kind of think about to growth? Number one. Number two, from an operational perspective, as you build efficiency and reduce complexity in the operational environment, how should we be thinking about how are you thinking about the need for potential incremental restructuring and the cash costs associated with

getting

to an end state that you're happy with?

I'd say, Steve, this is Amit here. I'd say, you know, I think it's a little premature to comment on on the specifics. I think as Kirk mentioned, right? Firstly, you know, right now the board's on the undertaking a strategic review that's looking at all, you know, potential alternatives and it's a broad range of alternatives. So I think, you know, and we'll keep you posted as that review develops. I think there is some operational complexity that Kirk mentioned. You know, we've got a long tail of skews that we can address fairly quickly. And so I think, you know, we'll get after that. But I think, you know, the overall, you know, once the strategic review as we progress that, I think, you know, that'll then inform, you know, the choices that we make. And like I said, it's a little premature right now to talk about, you know, the restructuring or associated cash costs. I think just on cash, I think if you see our results, you know, on cash flow this in the first half, we're ahead of last year. And that's largely driven by timing between last year and this year. But overall from a cash standpoint, I think, you know, despite the call down in earnings, I think, you know, our view is that we should be kind of in the same neighborhood as where we were last year.

Thank you. Our next question comes from the line of Felipo with the city. Please proceed with your question.

Hi, good morning, everyone. I wanted to ask two questions on the guidance, the updated guidance that you provided. Maybe first starting on top line. Is the expectation of a continuation of this low single digit declines in the back up? Or could you see a return to positive, a bit modest sales growth and maybe behind that, what are your expectation in terms of category growth inventory changes that retail are you assuming a continuation of this? And then second on the margins, it does imply your guidance of quite a bit of margin contraction. So maybe can you expand a bit of it? Does it come with tariff is the more investment that you've embedded in guidance? Just to give a bit of a shape of the of the PNL. Thank you.

I think, you know, if you look at, you know, given that we are giving guiding for a low single digit decline for the full year on the top line, and we close the first half at around minus two point seven. So, you know, the guidance range includes what we basically did in the first half and does not have to improve to be within the guidance. I think if you were to, you know, we do have more innovation as Kirk mentioned in the in the second half, and we know that in quarter four, we'll be lapping, you know, the trade accruals that happened last year. We'd be lapping the weakness in China that happened also in quarter four of twenty twenty four. So I would say if those two are incremental, we'd probably be towards the top end of the range. And at the bottom end of the range, you know, the assumption is those would not be incremental. I think, you know, the categories have softened. We've seen the categories soften in quarter two. And, you know, the sentiment of consumers is cautious. So

that's kind of what's been factored into the guidance.

Thank you. Our final questions will come from the line of Bonnie Herzog with Goldman Sachs. Please proceed with your question.

All right. Thank you. Good morning, everyone. I just had a quick question on Q3 trends. You know, some of the, I guess, declines you saw on Q2, you touched on this, but, you know, can be attributed to the later start in the summer, which did weigh on your seasonal businesses. So wondering if you see if you've seen that pick up in Q3 so far and, you know, if so, how much of a benefit do you see in Q3 a result of this shift? Also, you know, what are the other moving parts that we should keep in mind? You know, for instance, U.S. retailer inventory, destocking, you know, the China supply chain disruptions that are ultimately underpinning your largely flat to down, you know, organic sales growth guide in two H. Thank you.

So I think so far in July, you know, we're seeing similar trends to quarter two. So, you know, consumption is ahead of organic sales. I think, you know, the seasons are similar to what we saw. So, you know, seasons continue to be weak. Now, this has been incorporated into our guidance. I think, as I mentioned, you know, we have softer comps in quarter four when we comp the trade accrual as well as the China weakness. So I think, you know, that those are kind of the

puts and calls between the quarters.

Thank you. We have reached the end of our question and answer session. I would now like to turn the floor back over to Kirk Perry for concluding comments.

Yeah, thank you all for joining and we

appreciate the questions. We know we have work to do on this business and we look forward to continuing to share with you as we go forward. The choices we're making and, you know, as we continue to make these choices, improved business results. So thank you and we will talk to you all very soon.

Thank you. This concludes today's conference. Thank you. Thank you for your participation. Have a wonderful day. You may disconnect your lines at this time.